| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
A prospective multi-year clinical translational study including three cohorts of term infants experiencing their first Respiratory Syncytial Virus (RSV) season. All infants are less than or equal to nine months of age at study entry. The three subject cohorts represent the full spectrum of RSV disease severity and include a birth cohort, a cohort of infants hospitalized for RSV disease and infants evaluated at ambulatory settings for RSV infection. All infants are followed longitudinally and evaluated at recognition of acute RSV infection and twice during convalescence. Innate and adaptive immune status are comprehensively measured in association with clinical, environmental, viral, and bacteriologic factors. Genome-wide expression is assessed in the nasal airways, and in sorted peripheral blood lymphocytes. The study goal is to Identify host responses to RSV infection and factors associated with severe disease.
- Study Weblinks:
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Longitudinal
- Total number of consented subjects: 186
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
Inclusion criteria:
- Gestational age >=36 weeks and in good health at birth discharge
- Parent/guardian can provide informed consent
- Infant will be available for duration of the study
- Acute illness documented to be due to RSV infection (hospital cohort only)
- Born after the previous May 1st
Exclusion criteria:
- Any infant eligible to receive RSV prophylaxis with Palivizumab
- Presence of underlying neuromuscular disorder (i.e., Down's syndrome, cerebral palsy)
- Immunosuppressive condition (i.e., HIV infection in mother) or use of immunosuppressive medications prior to RSV infection
- Presence of malignancy (i.e., Wilms tumor)
- Inability to contact for the duration of the study
- Any other condition deemed to place infant at higher risk for severe RSV infection (i.e., NICU transfer at birth, recurrent aspiration)
- Infants hospitalized for apnea only (hospital cohort only)
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment RNA Sequencing Illumina HiSeq 2500 N/A N/A 16S rRNA Sequencing Illumina MiSeq N/A N/A - Study History
- October 2012 - April 2013: RSV season 1
- August 2013 - May 2014: RSV season 2
- November 2014 - April 2015: RSV season 3
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Respiratory Syncytial Virus Infections
- Infant
- Links to Related Genes
- Authorized Data Access Requests
-
See articles in PMC citing this study accession
- Study Attribution
-
-
Principal Investigator
- Edward E. Walsh, M.D. University of Rochester Medical Center, Rochester, NY, USA.
-
Investigators
- Mary T. Caserta, M.D. University of Rochester Medical Center, Rochester, NY, USA.
- Tom Mariani, PhD. University of Rochester Medical Center, Rochester, NY, USA.
- Steven Gill, PhD. University of Rochester Medical Center, Rochester, NY, USA.
- David Topham, PhD. University of Rochester Medical Center, Rochester, NY, USA.
-
Funding Source
- HHSN272201200005C (Respiratory Pathogens Research Center). National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator